Opinion|Videos|October 10, 2024

ESMO 2024: Key Updates From NICHE-2

Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.


Latest CME